請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51794
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭錦樺 | |
dc.contributor.author | Hsi-Chun Chao | en |
dc.contributor.author | 趙錫均 | zh_TW |
dc.date.accessioned | 2021-06-15T13:50:08Z | - |
dc.date.available | 2021-02-26 | |
dc.date.copyright | 2016-02-26 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-10-21 | |
dc.identifier.citation | 1. Nicholson, J.K., J.C. Lindon, and E. Holmes, 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica, 1999. 29(11): p. 1181-1189.
2. Wishart, D.S., et al., HMDB: the Human Metabolome Database. Nucleic Acids Research, 2007. 35(suppl 1): p. D521-D526. 3. Wenk, M.R., The emerging field of lipidomics. Nat Rev Drug Discov, 2005. 4(7): p. 594-610. 4. Watson, A.D., Thematic review series: Systems Biology Approaches to Metabolic and Cardiovascular Disorders. Lipidomics: a global approach to lipid analysis in biological systems. Journal of Lipid Research, 2006. 47(10): p. 2101-2111. 5. Wenk, M.R., Lipidomics: New Tools and Applications. Cell, 2010. 143(6): p. 888-895. 6. Merrill Jr, A.H., et al., Sphingolipids—The Enigmatic Lipid Class: Biochemistry, Physiology, and Pathophysiology. Toxicology and Applied Pharmacology, 1997. 142(1): p. 208-225. 7. Hannun, Y.A. and L.M. Obeid, Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol, 2008. 9(2): p. 139-150. 8. Pettus, B.J., C.E. Chalfant, and Y.A. Hannun, Ceramide in apoptosis: an overview and current perspectives. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2002. 1585(2–3): p. 114-125. 9. Jana, A., E.L. Hogan, and K. Pahan, Ceramide and neurodegeneration: Susceptibility of neurons and oligodendrocytes to cell damage and death. Journal of the Neurological Sciences, 2009. 278(1–2): p. 5-15. 10. Lépine, S., et al., Autophagy Induced by Deficiency of Sphingosine-1-phosphate Phosphohydrolase 1 Is Switched to Apoptosis by Calpain-mediated Autophagy-related Gene 5 (Atg5) Cleavage. Journal of Biological Chemistry, 2011. 286(52): p. 44380-44390. 11. Evans, G.A., Designer science and the [ldquo]omic[rdquo] revolution. Nat Biotech, 2000. 18(2): p. 127-127. 12. Fiehn, O., Metabolomics – the link between genotypes and phenotypes. Plant Molecular Biology, 2002. 48(1-2): p. 155-171. 13. German, J.B., B. Hammock, and S. Watkins, Metabolomics: building on a century of biochemistry to guide human health. Metabolomics, 2005. 1(1): p. 3-9. 14. Weljie, A.M., et al., Targeted Profiling: Quantitative Analysis of 1H NMR Metabolomics Data. Analytical Chemistry, 2006. 78(13): p. 4430-4442. 15. Lin, C., et al., Evaluation of metabolite extraction strategies from tissue samples using NMR metabolomics. Metabolomics, 2007. 3(1): p. 55-67. 16. Brown, S.C., G. Kruppa, and J.-L. Dasseux, Metabolomics applications of FT-ICR mass spectrometry. Mass Spectrometry Reviews, 2005. 24(2): p. 223-231. 17. Soga, T., et al., Quantitative Metabolome Analysis Using Capillary Electrophoresis Mass Spectrometry. Journal of Proteome Research, 2003. 2(5): p. 488-494. 18. De Vos, R.C.H., et al., Untargeted large-scale plant metabolomics using liquid chromatography coupled to mass spectrometry. Nat. Protocols, 2007. 2(4): p. 778-791. 19. Dettmer, K., P.A. Aronov, and B.D. Hammock, MASS SPECTROMETRY-BASED METABOLOMICS. Mass spectrometry reviews, 2007. 26(1): p. 51-78. 20. Gullberg, J., et al., Design of experiments: an efficient strategy to identify factors influencing extraction and derivatization of Arabidopsis thaliana samples in metabolomic studies with gas chromatography/mass spectrometry. Analytical Biochemistry, 2004. 331(2): p. 283-295. 21. Goodacre, R., et al., Metabolomics by numbers: acquiring and understanding global metabolite data. Trends in Biotechnology, 2004. 22(5): p. 245-252. 22. Castelli, W.P., et al., HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation, 1977. 55(5): p. 767-72. 23. Maxfield, F.R. and I. Tabas, Role of cholesterol and lipid organization in disease. Nature, 2005. 438(7068): p. 612-621. 24. Wymann, M.P. and R. Schneiter, Lipid signalling in disease. Nat Rev Mol Cell Biol, 2008. 9(2): p. 162-176. 25. Testai, F.D., et al., Multiple sphingolipid abnormalities following cerebral microendothelial hypoxia. Journal of Neurochemistry, 2014. 131(4): p. 530-540. 26. Walls, S.M., Jr., et al., Identification of Sphingolipid Metabolites That Induce Obesity via Misregulation of Appetite, Caloric Intake and Fat Storage in <italic>Drosophila</italic>. PLoS Genet, 2013. 9(12): p. e1003970. 27. Yu, J., et al., JNK3 Signaling Pathway Activates Ceramide Synthase Leading to Mitochondrial Dysfunction. Journal of Biological Chemistry, 2007. 282(35): p. 25940-25949. 28. Yu, Z., et al., Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis. Journal of Molecular Neuroscience, 2000. 15(2): p. 85-97. 29. Mielke, M.M., et al., Serum ceramides increase the risk of Alzheimer disease: The Women's Health and Aging Study II. Neurology, 2012. 79(7): p. 633-641. 30. Ogretmen, B. and Y.A. Hannun, Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer, 2004. 4(8): p. 604-616. 31. Slotte, J.P. and B. Ramstedt, The functional role of sphingomyelin in cell membranes. European Journal of Lipid Science and Technology, 2007. 109(10): p. 977-981. 32. Xu, X., et al., Effect of the Structure of Natural Sterols and Sphingolipids on the Formation of Ordered Sphingolipid/Sterol Domains (Rafts): COMPARISON OF CHOLESTEROL TO PLANT, FUNGAL, AND DISEASE-ASSOCIATED STEROLS AND COMPARISON OF SPHINGOMYELIN, CEREBROSIDES, AND CERAMIDE. Journal of Biological Chemistry, 2001. 276(36): p. 33540-33546. 33. Jana, A. and K. Pahan, Sphingolipids in multiple sclerosis. Neuromolecular medicine, 2010. 12(4): p. 351-361. 34. Oku, H., et al., Tumor specific cytotoxicity of glucosylceramide. Cancer Chemotherapy and Pharmacology, 2007. 60(6): p. 767-775. 35. Haynes, C.A., et al., Sphingolipidomics: Methods for the comprehensive analysis of sphingolipids. Journal of Chromatography B, 2009. 877(26): p. 2696-2708. 36. Wang, J.-R., et al., Improved Sphingolipidomic Approach Based on Ultra-High Performance Liquid Chromatography and Multiple Mass Spectrometries with Application to Cellular Neurotoxicity. Analytical Chemistry, 2014. 86(12): p. 5688-5696. 37. Bligh, E.G. and W.J. Dyer, A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION. Canadian Journal of Biochemistry and Physiology, 1959. 37(8): p. 911-917. 38. Merrill Jr, A.H., et al., Sphingolipidomics: High-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods, 2005. 36(2): p. 207-224. 39. Gu, M., et al., Ceramide Profiling of Complex Lipid Mixtures by Electrospray Ionization Mass Spectrometry. Analytical Biochemistry, 1997. 244(2): p. 347-356. 40. Xia, Y.-Q. and M. Jemal, Phospholipids in liquid chromatography/mass spectrometry bioanalysis: comparison of three tandem mass spectrometric techniques for monitoring plasma phospholipids, the effect of mobile phase composition on phospholipids elution and the association of phospholipids with matrix effects. Rapid Communications in Mass Spectrometry, 2009. 23(14): p. 2125-2138. 41. Liebisch, G., et al., High-throughput quantification of phosphatidylcholine and sphingomyelin by electrospray ionization tandem mass spectrometry coupled with isotope correction algorithm. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2004. 1686(1–2): p. 108-117. 42. Patti, G.J., O. Yanes, and G. Siuzdak, Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol, 2012. 13(4): p. 263-269. 43. Kell, D.B., Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discovery Today, 2006. 11(23–24): p. 1085-1092. 44. Griffin, J.L. and J.P. Shockcor, Metabolic profiles of cancer cells. Nat Rev Cancer, 2004. 4(7): p. 551-561. 45. Robertson, D.G., P.B. Watkins, and M.D. Reily, Metabolomics in Toxicology: Preclinical and Clinical Applications. Toxicological Sciences, 2011. 120(suppl 1): p. S146-S170. 46. Panopoulos, A.D., et al., The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res, 2012. 22(1): p. 168-177. 47. Wu, Y. and L. Li, Determination of Total Concentration of Chemically Labeled Metabolites as a Means of Metabolome Sample Normalization and Sample Loading Optimization in Mass Spectrometry-Based Metabolomics. Analytical Chemistry, 2012. 84(24): p. 10723-10731. 48. Silva, L.P., et al., Measurement of DNA concentration as a normalization strategy for metabolomic data from adherent cell lines. Analytical chemistry, 2013. 85(20): p. 10.1021/ac401559v. 49. Wu, Y. and L. Li, Dansylation Metabolite Assay: A Simple and Rapid Method for Sample Amount Normalization in Metabolomics. Analytical Chemistry, 2014. 86(19): p. 9428-9433. 50. Alberts, B., et al., Molecular Biology of the Cell. 2007: Garland Science. 51. Vance, J.E., Thematic Review Series: Glycerolipids. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. Journal of Lipid Research, 2008. 49(7): p. 1377-1387. 52. Fagone, P. and S. Jackowski, Phosphatidylcholine and the CDP–choline cycle. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013. 1831(3): p. 523-532. 53. Dymond, M.K., et al., An in vivo ratio control mechanism for phospholipid homeostasis: evidence from lipidomic studies. Journal of The Royal Society Interface, 2012. 10(80). 54. Mozaffarian, D., et al., Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association. Circulation, 2015. 131(4): p. e29-e322. 55. Plesnila, N., et al., BID mediates neuronal cell death after oxygen/ glucose deprivation and focal cerebral ischemia. Proceedings of the National Academy of Sciences of the United States of America, 2001. 98(26): p. 15318-15323. 56. Ariga, T., W.D. Jarvis, and R.K. Yu, Role of sphingolipid-mediated cell death in neurodegenerative diseases. Journal of Lipid Research, 1998. 39(1): p. 1-16. 57. Li, Y., P. Maher, and D. Schubert, Phosphatidylcholine-specific phospholipase C regulates glutamate-induced nerve cell death. Proceedings of the National Academy of Sciences, 1998. 95(13): p. 7748-7753. 58. Edmands, W.M.B., P. Ferrari, and A. Scalbert, Normalization to Specific Gravity Prior to Analysis Improves Information Recovery from High Resolution Mass Spectrometry Metabolomic Profiles of Human Urine. Analytical Chemistry, 2014. 86(21): p. 10925-10931. 59. Wu, B., C. Clarke, and Y. Hannun, Mammalian Neutral Sphingomyelinases: Regulation and Roles in Cell Signaling Responses. NeuroMolecular Medicine, 2010. 12(4): p. 320-330. 60. Kelly-Hayes, M., et al., The influence of gender and age on disability following ischemic stroke: the Framingham study. Journal of Stroke and Cerebrovascular Diseases, 2003. 12(3): p. 119-126. 61. Jauch, E.C., et al., Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2013. 44(3): p. 870-947. 62. Lindsberg, P.J., J.M. Hallenbeck, and G. Feuerstein, Platelet-activating factor in stroke and brain injury. Annals of Neurology, 1991. 30(2): p. 117-129. 63. Ohira, T., et al., Risk Factors for Ischemic Stroke Subtypes: The Atherosclerosis Risk in Communities Study. Stroke, 2006. 37(10): p. 2493-2498. 64. Yamada, Y., et al., Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis, 2000. 150(1): p. 209-216. 65. Nilupul Perera, M., et al., Inflammation following stroke. Journal of Clinical Neuroscience, 2006. 13(1): p. 1-8. 66. Mena, H., D. Cadavid, and E. Rushing, Human cerebral infarct: a proposed histopathologic classification based on 137 cases. Acta Neuropathologica, 2004. 108(6): p. 524-530. 67. Pedersen, E.D., et al., Systemic complement activation following human acute ischaemic stroke. Clinical & Experimental Immunology, 2004. 137(1): p. 117-122. 68. Meyers, P.M., et al., Current Status of Endovascular Stroke Treatment. Circulation, 2011. 123(22): p. 2591-2601. 69. Di Napoli, M., F. Papa, and V. Bocola, C-Reactive Protein in Ischemic Stroke: An Independent Prognostic Factor. Stroke, 2001. 32(4): p. 917-924. 70. Doi, Y., et al., Elevated C-Reactive Protein Is a Predictor of the Development of Diabetes in a General Japanese Population: The Hisayama Study. Diabetes Care, 2005. 28(10): p. 2497-2500. 71. Ramos, L.F., et al., Oxidative Stress and Inflammation Are Associated with Adiposity in Moderate to Severe CKD. Journal of the American Society of Nephrology, 2008. 19(3): p. 593-599. 72. VanGilder, R.L., et al., C-reactive protein and long-term ischemic stroke prognosis. Journal of Clinical Neuroscience, 2014. 21(4): p. 547-553. 73. Meschia, J.F., et al., Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2014. 45(12): p. 3754-3832. 74. Lawrence, T., D.A. Willoughby, and D.W. Gilroy, Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol, 2002. 2(10): p. 787-795. 75. Farooqui, A.A., L.A. Horrocks, and T. Farooqui, Interactions between neural membrane glycerophospholipid and sphingolipid mediators: A recipe for neural cell survival or suicide. Journal of Neuroscience Research, 2007. 85(9): p. 1834-1850. 76. Tang, S.-C., et al., Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proceedings of the National Academy of Sciences, 2007. 104(34): p. 13798-13803. 77. Lorenz, M.A., C.F. Burant, and R.T. Kennedy, Reducing Time and Increasing Sensitivity in Sample Preparation for Adherent Mammalian Cell Metabolomics. Analytical Chemistry, 2011. 83(9): p. 3406-3414. 78. Arumugam, T.V., et al., Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion. Vol. 287. 2004. H2555-H2560. 79. Devlin, C.M., et al., Dihydroceramide-based Response to Hypoxia. Journal of Biological Chemistry, 2011. 286(44): p. 38069-38078. 80. Haimovitz-Friedman, A., R.N. Kolesnick, and Z. Fuks, Ceramide signaling in apoptosis. British Medical Bulletin, 1997. 53(3): p. 539-553. 81. Bleicher, R.J. and M.C. Cabot, Glucosylceramide synthase and apoptosis. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2002. 1585(2–3): p. 172-178. 82. Devlin, C.M., et al., Dihydroceramide-based response to hypoxia. The Journal of Biological Chemistry, 2012. 287(21): p. 17425-17425. 83. Kang, M.S., et al., Hypoxia-induced neuronal apoptosis is mediated by de novo synthesis of ceramide through activation of serine palmitoyltransferase. Cellular Signalling, 2010. 22(4): p. 610-618. 84. Memon, R.A., et al., Regulation of sphingolipid and glycosphingolipid metabolism in extrahepatic tissues by endotoxin. Journal of Lipid Research, 2001. 42(3): p. 452-459. 85. Farrell, A.M., et al., UVB irradiation up-regulates serine palmitoyltransferase in cultured human keratinocytes. Journal of Lipid Research, 1998. 39(10): p. 2031-2038. 86. Horres, C. and Y. Hannun, The Roles of Neutral Sphingomyelinases in Neurological Pathologies. Neurochemical Research, 2012. 37(6): p. 1137-1149. 87. Soeda, S., et al., Inhibition of sphingomyelinase activity helps to prevent neuron death caused by ischemic stress. Neurochemistry International, 2004. 45(5): p. 619-626. 88. Claus, R.A., et al., Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate. Current Medicinal Chemistry, 2009. 16(16): p. 1978-2000. 89. Tian, H.-p., et al., Sphingomyelinase-induced ceramide production stimulate calcium-independent JNK and PP2A activation following cerebral ischemia. Brain Injury, 2009. 23(13-14): p. 1073-1080. 90. Testai, F.D., et al., Changes in the Cerebrospinal Fluid Ceramide Profile After Subarachnoid Hemorrhage. Stroke, 2012. 43(8): p. 2066-2070. 91. Hannun, Y.A. and L.M. Obeid, Many Ceramides. Journal of Biological Chemistry, 2011. 286(32): p. 27855-27862. 92. White-Gilbertson, S., et al., Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene, 2009. 28(8): p. 1132-1141. 93. Martin-Villalba, A., et al., CD95 Ligand (Fas-L/APO-1L) and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Mediate Ischemia-Induced Apoptosis in Neurons. The Journal of Neuroscience, 1999. 19(10): p. 3809-3817. 94. Herget, T., et al., Production of Ceramides Causes Apoptosis during Early Neural Differentiation in Vitro. Journal of Biological Chemistry, 2000. 275(39): p. 30344-30354. 95. Grösch, S., S. Schiffmann, and G. Geisslinger, Chain length-specific properties of ceramides. Progress in Lipid Research, 2012. 51(1): p. 50-62. 96. Mesicek, J., et al., Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cellular Signalling, 2010. 22(9): p. 1300-1307. 97. Menuz, V., et al., Protection of C. elegans from Anoxia by HYL-2 Ceramide Synthase. Science, 2009. 324(5925): p. 381-384. 98. Pyne, N.J. and S. Pyne, Sphingosine 1-phosphate and cancer. Nat Rev Cancer, 2010. 10(7): p. 489-503. 99. Okazaki, M., et al., Sphingosine 1-Phosphate Inhibits Ischemia Reperfusion Injury Following Experimental Lung Transplantation. American Journal of Transplantation, 2007. 7(4): p. 751-758. 100. Hasegawa, Y., et al., Activation of Sphingosine 1-Phosphate Receptor-1 by FTY720 Is Neuroprotective After Ischemic Stroke in Rats. Stroke, 2010. 41(2): p. 368-374. 101. Signorelli, P., et al., Dihydroceramide intracellular increase in response to resveratrol treatment mediates autophagy in gastric cancer cells. Cancer Letters, 2009. 282(2): p. 238-243. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51794 | - |
dc.description.abstract | 鞘脂是生物中脂類的一種,研究指出其和許多病理生理功能相關,例如細胞凋亡。中風是一個與腦血管相關的嚴重疾病,而在文獻報導中,鞘脂有可能與缺血所引發的神經受損相關,然而缺乏全面性的鞘脂分析於缺血性神經受損的關聯,使研究者難以分辨不同鞘脂,對於缺血性中風的影響,因此,一個能夠完整且無偏差的鞘脂分析平台,對於鞘脂之代謝途徑以及缺血引起神經元受損研究,是非常重要的,藉此才能有效分析討論鞘脂對於缺血性神經受損所牽涉之生理功能。
在本論文第一章,我們建立了一個鞘脂體的分析平台,並且開發了一個針對細胞脂質體學的校正方法。我們利用液相層析搭配電噴灑離子源串聯質譜儀(LC-ESI-MS)能夠偵測87種不同的鞘脂,並且改良了萃取方法,達到快速且和具良好回收率的萃取結果。我們也開發了一個新的細胞脂質體學的濃度校正方法,使用流動注射搭配電噴灑離子源串聯質譜儀(FIA-ESI-MS)搭配先驅離子掃描(Precursor ion scan, PIS)來偵測荷質比(m/z)為184的離子(PIS of 184),藉此來估計樣品相對濃度,並以此為基準進行樣品稀釋,使不同細胞樣品能夠在相似濃度下進行,而減少研究結果的誤差。此利用PIS of 184的方法經準確度與同日以及異日間精密度測試,其準確度在不同稀釋細胞倍數為93.0% 至105.6%,同日間精密度誤差皆小於5%,而異日間精密度誤差也小於10%,並且我們利用HCT-116的細胞株與其他常用細胞濃度校正方法進行比較,本方法和細胞計量以及DNA濃度的方法之校正結果皆具有高度關聯性。 在本論文第二章,我們利用建立的鞘脂體學分析平台以及新的細胞脂質體學的校正方法,針對經過大腦中動脈阻塞之小鼠模型以及氧糖剝奪之神經細胞模型來進行缺血及復氧的鞘脂體學分析。在使用建立的鞘脂體分析平台,共偵測得47個不同鞘脂於小鼠腦樣品以及28個不同鞘脂於神經細胞樣品。針對不同鞘脂分析,結果顯示小鼠模型和神經細胞模型具有類似趨勢,因此我們再針對神經細胞進行鞘脂分析比對而得,在Sphinganine、dihydroceramides、短碳鍊的ceramides (碳側鍊小於20個碳) 和sphingosine在氧糖剝奪後有顯著的增加,而 sphingomyelins和長碳鍊ceramides則是顯著的減少,同時我們發現不同的鞘脂會隨著氧糖剝奪與復氧,在代謝上會隨著不同的時間而有變化,我們基於此結果建構出了鞘脂類在缺血下可能的代謝途徑,並且同時針對此現象討論可能造成神經損傷的原因。 本論文主要貢獻在於建立一個鞘脂體學分析平台以及開發一個利用PIS of 184針對細胞脂質體學的校正方法,並且成功應用於探討鞘脂在缺血所引起之神經損傷。 | zh_TW |
dc.description.abstract | Sphingolipids (SPLs) are a type of lipid subgroup, and some SPLs have been reported to be associated to many different pathological pathways such as cell apoptosis. Stroke is a serious cerebrovascular-associated disease. Previous studies showed that SPLs play important roles in ischemic stroke induced neuron injury. However, the lack of comprehensive analysis between sphingolipids metabolism and ischemia induced neuron injury has hindered the identification of specific pathophysiological roles of different sphingolipids. Therefore, it is important to have an efficient and comprehensive analytical platform to elucidate the relationship between ischemia induced neuron injury and SPLs concentration changes.
We established a sphingolipidomic analytical platform and a concentration normalization method for cellular lipidomic studies in the first chapter of this thesis. Using the optimized LC-ESI-MS conditions, the established sphingolipidomic analytical platform is able to identify 87 sphingolipids. The sphingolipid extraction method provided comparable recoveries when compared with previous methods, but required shorter extraction time. We further developed a new normalization method to improve data integrity for cellular lipidomic studies. The flow-injection-analysis coupled with electro-spray ionization read by a triple quadruple mass spectrometer (FIA-ESI-QQQ) method using precursor ion scan (PIS) of ion 184 was used to estimate relative concentration. Samples were further diluted to analyze all samples at a similar concentration level. The “PIS of 184” method was validated with accuracy, intraday and intermediate precision. We used HCT-116 cell models for normalization method comparison and the results showed good correlations with cell counts (R=0.97) and DNA concentration (R=0.95) methods. In the second chapter, we further investigate ischemia induced neuron injury through the application of the established sphingolipid analytical platform to a C57BL/6J mice model receiving middle cerebral artery occlusion (MCAO) and primary cultured rat neurons with oxygen and glucose deprivation (OGD) for ischemia-reperfusion (I/R) study. A total of 47 sphingolipids were detected in the brain and 28 sphingolipids were detected in neuron cells. The mice brain results showed similar trends to the neurons in terms of SPL concentration changes, and we therefore used primary neurons with OGD-treatment to study SPL concentration changes in association with ischemia induced neuron injury. Sphinganine, dihydroceramides, short-chain ceramides (acyl chain < 20C), and sphingosine were significantly increased, and sphingomyelins and long-chain ceramides were decreased after OGD treatment. Temporal changes of SPLs after OGD treatment were used to investigate the roles of SPLs in ischemia induced neuron injury. The observed changes in the metabolic pathway of SPLs after ischemia induced neuron injury were also reported in this section of the thesis. In conclusion, we established a sphingolipidomics analytical platform with a new normalization strategy using PIS of 184 and successfully applied the method to the investigation of ischemia induced neuron injury. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T13:50:08Z (GMT). No. of bitstreams: 1 ntu-104-R02423003-1.pdf: 19365231 bytes, checksum: 5df16d25f1182577a6dd9dec6f3ffb58 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | Figure Contents 3
Table Contents 5 Abstract 6 Preface 9 Chapter 1 11 Chapter 1.1 12 1. Introduction 13 2. Material and methods 17 2.1 Chemicals 17 2.2 UPLC-MS/MS system 17 2.3 Analytical procedures 17 2.4 Extraction procedures 18 3. Method development 20 3.1. Extraction 20 3.2. LC-MS/MS 20 4. Identification of SPLs 21 5. Figures and tables 24 Chapter 1.2 36 1. Introduction 37 2. Material and methods 40 2.1 Chemicals 40 2.2 Cell culture 40 2.3 Sample preparation (Lipidomic analysis assay) 41 2.4 Cell counting assay 42 2.5 DNA concentration assay 42 2.6 Protein concentration assay 43 2.7 FIA-ESI-QQQ procedure 44 2.8 Analysis of sphingolipids 44 2.9 PC analysis procedure 45 3. Results and discussion 47 3.1. Total PC and SM are conserved in same number of cells and can be used for concentration normalization in lipidomic studies 47 3.2. Optimization of FIA-ESI-QQQ of precursor ion scan of 184 analytical conditions 48 3.3. Method validation 49 3.4. Performance of the PIC 184 method for concentration normalization in lipidomic studies 50 3.5. Using PIS of 184 for concentration normalization for lipidomic analysis on OGD induced neuron injury 53 4. Figures and tables 55 Conclusion 76 Chapter 2 78 1. Introduction 79 2. Materials and methods 82 2.1 Chemicals 82 2.2 Analysis of sphingolipids 82 2.3 Cell culture and OGD treatment 83 2.4 MCAO procedure 84 2.5 Sample preparations 85 3. Results 86 3.1. The sphingolipidomic results of MCAO treatment in mice brains 87 3.2. The sphigolipidmic results of OGD treatment of rat neurons 88 4. Discussion 90 5. Conclusion 96 6. Figures 97 Reference 110 | |
dc.language.iso | en | |
dc.title | 開發細胞脂質體學之濃度校正方法與使用鞘脂體學方法研究缺血引發之神經細胞損傷 | zh_TW |
dc.title | Development of the Concentration Normalization Method for Cellular Lipidomic Studies and Sphingolipidomic Investigation of Ischemia Induced Neuron Injury | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 湯頌君,汪海晏 | |
dc.subject.keyword | 鞘質體學,缺血性中風,神經損傷,濃度校正方法, | zh_TW |
dc.subject.keyword | Sphingolipidomics,Stroke,Ishchemia,Neuron Injury,Concentration Normalization Strategy, | en |
dc.relation.page | 116 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-10-21 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 18.91 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。